Cathie Wood’s Top 5 Small-Cap Stock Picks

2. Fate Therapeutics, Inc. (NASDAQ:FATE)

Number of Hedge Fund Holders: 31

Cathie Wood’s Ark Investment Management’s Holdings: $265,041,000

Percentage of Cathie Wood’s Ark Investment Management’s Portfolio: 1.56%

Market Capitalization as of July 26: $2.97 billion

Fate Therapeutics, Inc. (NASDAQ:FATE) is a La Jolla, California-based biotech company focused on the development of immunotherapies to fight against cancer.

Fate Therapeutics, Inc. (NASDAQ:FATE) has its proprietary platform to generate cell therapy products. On July 11, Etzer Darout at BMO Capital upgraded Fate Therapeutics, Inc. (NASDAQ:FATE) stock from a Market Perform to an Outperform rating but revised the target price from $50 to $47. The analyst thinks that Fate Therapeutics, Inc.’s (NASDAQ:FATE) induced pluripotent stem cells (iPSCs) platform is uniquely positioned in the cell therapy space.

Overall, 31 hedge funds held a cumulative stake of $1.26 billion in Fate Therapeutics, Inc. (NASDAQ:FATE) at the end of Q1 2022.